Patents by Inventor Christopher U. Missling

Christopher U. Missling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of cardiac dysfunction
    Patent number: 11071723
    Abstract: A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or pharmaceutically acceptable salt thereof or combination thereof.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: July 27, 2021
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
    Publication number: 20210196708
    Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(pheny)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
    Type: Application
    Filed: February 12, 2021
    Publication date: July 1, 2021
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY
    Publication number: 20210186920
    Abstract: A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
    Type: Application
    Filed: November 28, 2018
    Publication date: June 24, 2021
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. MISSLING
  • A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF
    Publication number: 20210115004
    Abstract: The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.
    Type: Application
    Filed: April 12, 2019
    Publication date: April 22, 2021
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. MISSLING
  • A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY, AND AGITATION
    Publication number: 20210085637
    Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.
    Type: Application
    Filed: July 27, 2017
    Publication date: March 25, 2021
    Inventor: Christopher U. Missling
  • Analgesic therapeutic and method, 1-(3-4(((1 R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
    Patent number: 10933062
    Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: March 2, 2021
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy
    Publication number: 20210046038
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with any therapeutically effective amount of an AED.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 18, 2021
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • Neurodevelopmental disorder therapy
    Patent number: 10888543
    Abstract: This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: January 12, 2021
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
    Patent number: 10813907
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with an therapeutically effective amount of an AED.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: October 27, 2020
    Assignee: ANAVEX LIFE SCINCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • Neurodevelopmental Disorder Therapy
    Publication number: 20200246303
    Abstract: This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Application
    Filed: December 17, 2019
    Publication date: August 6, 2020
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. MISSLING
  • A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy
    Publication number: 20200038365
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with an therapeutically effective amount of an AED.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • Neurodevelopmental disorder therapy
    Patent number: 10507196
    Abstract: This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: December 17, 2019
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
    Publication number: 20190167668
    Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Inventor: Christopher U. Missling
  • TREATMENT OF CARDIAC DYSFUNCTION
    Publication number: 20190117615
    Abstract: A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or pharmaceutically acceptable salt thereof or combination thereof.
    Type: Application
    Filed: October 22, 2018
    Publication date: April 25, 2019
    Inventor: Christopher U. Missling
  • Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
    Patent number: 10195192
    Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: February 5, 2019
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • NEURODEVELOPMENTAL DISORDER THERAPY
    Publication number: 20190022052
    Abstract: This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Application
    Filed: January 24, 2017
    Publication date: January 24, 2019
    Inventor: Christopher U. Missling
  • Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
    Publication number: 20180117035
    Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
    Type: Application
    Filed: November 1, 2016
    Publication date: May 3, 2018
    Inventor: Christopher U. Missling